

---

**Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia, Japan, Hong Kong, New Zealand, South Africa or any other jurisdiction where such distribution of this press release would be subject to legal restrictions**

---



## **Meda's rights issue fully subscribed**

The result of Meda AB's rights issue, for which the subscription period ended on 4 December 2014, indicates that approximately 33.1 million shares, representing approximately 99.7 percent of the offered shares, were subscribed for by the exercise of subscription rights. In addition, subscription forms for subscription without subscription rights, corresponding to approximately 47.4 million shares and to approximately 142.6 percent of the offered shares, have been received. Thus, the rights issue is fully subscribed. Through the rights issue, Meda will receive proceeds amounting to approximately SEK 2,027 million before issue expenses.

Those who have subscribed for shares without subscription rights will be allotted shares according to the principles described in the prospectus. Such subscribers who have been allotted shares without preferential rights are expected to be notified on 11 December 2014. Only those who are allotted shares will be notified.

Through the rights issue, Meda's share capital increases by SEK 33,224,306, from SEK 332,243,065 to SEK 365,467,371, and the total number of shares increases by 33,224,306, from 332,243,065 to 365,467,371. The new shares subscribed for with subscription rights are expected to be registered at the Swedish Companies Registration Office on or about 11 December 2014. Shares subscribed for without subscription rights are expected to be registered at the Swedish Companies Registration Office on or about 17 December 2014.

The final day for trading in paid subscribed shares (BTAs) is expected to be on 17 December 2014. The new shares are expected to start trading on Nasdaq Stockholm on 19 December 2014.

Danske Bank A/S, Danmark, Sverige Filial, Nordea Bank AB (publ) and SEB Corporate Finance, Skandinaviska Enskilda Banken AB (publ) are acting as financial advisors and Advokatfirman Lindahl KB is acting as legal advisor to Meda in connection with the rights issue.

---

**For further inquiries, please contact:**

Paula Treutiger, VP Corporate Communications & Sustainability

ph: +46 733-666 599

paula.treutiger@meda.se

---

Meda AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on December 10, 2014, at 10:00 CET.

**MEDA AB (publ)** is a leading international specialty pharma company. Meda's products are sold in more than 150 countries worldwide and the company is represented by its own organizations in over 60 countries. The Meda share is listed under Large Cap on Nasdaq Stockholm. Find out more, visit [www.meda.se](http://www.meda.se).

**Important information**

The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares, subscription rights or other securities in Meda. Any invitation to the persons concerned to subscribe for shares in Meda will only be made through the prospectus which was published by Meda on 14 November 2014.

This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, New Zealand, South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish, Danish or English law. Nor may the information in this press release be forwarded, reproduced or disclosed in a manner that contravenes such restrictions or would entail such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares have or will be registered under the U.S. Securities Act of 1933, as amended, ("Securities Act") or securities legislation in any state or other jurisdiction in the United States and may not be offered or sold, directly or indirectly, in or into the United States, except pursuant to an available exemption from the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States.

This press release may contain forward-looking statements which reflect Meda's current view on future events and financial and operational development. The words "intend", "estimate", "expect", "may", "plan", "anticipate" or similar expressions regarding indications or predictions of future developments or trends and which are not statements based on historical facts constitute forward-looking information. Although Meda believes that these statements are based on reasonable assumptions and expectations, Meda cannot give any assurances that such statements will materialize. Forward-looking statements are in its nature involved with both known and unknown risks and uncertainties, since it is depending on future events and circumstances. Forward-looking statements do not constitute any representations and warranties and the outcome could differ materially from the information set out in the forward-looking statements.